Sector Update: Healthcare


Healthcare shares are mixed in pre-market trade.

Amarin ( AMRN ) is up 15.1% pre-market after it said the FDA does not expect to take action on AMRN's supplemental new drug application (sNDA) for the proposed ANCHOR indication labeling expansion for Vascepa capsules on the December 20 Prescription Drug User Fee Act (PDUFA) goal date because AMRN's request to re-instate the ANCHOR Special Protocol Assessment agreement remains under consideration with the FDA. No new PDUFA date was established.

Apricus Biosciences ( APRI ) is up 7.9% at $2.04 in the pre-market session after it said late yesterday that the National Agency for Medicines and Health Products Safety has granted national phase approval to Vitaros, indicated for the treatment of patients with erectile dysfunction.

Vitaros is expected to become the first new and novel erectile dysfunction product launched in nearly a decade. It will be marketed in France by APRI's commercialization partner, Laboratories Majorelle.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , Commodities

Referenced Stocks: AMRN , APRI

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by